Patents by Inventor Tetsuji Matsudaira

Tetsuji Matsudaira has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF
    Publication number: 20240390387
    Abstract: Provided is a compound or a pharmaceutically acceptable salt thereof which is superior in an action inducing degradation of BRD4 protein and useful as a therapeutic agent for cancer. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the DESCRIPTION.
    Type: Application
    Filed: August 6, 2024
    Publication date: November 28, 2024
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Kiyomi OHBA, Yasuki NIWA, Tetsuji MATSUDAIRA, Maiko HAMADA, Ryuta YAMAZAKI, Tatsuya IBUKI
  • Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof
    Patent number: 12102641
    Abstract: Provided is a compound or a pharmaceutically acceptable salt thereof which is superior in an action inducing degradation of BRD4 protein and useful as a therapeutic agent for cancer. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the DESCRIPTION.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: October 1, 2024
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Kiyomi Ohba, Yasuki Niwa, Tetsuji Matsudaira, Maiko Hamada, Ryuta Yamazaki, Tatsuya Ibuki
  • Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof
    Patent number: 11890288
    Abstract: Provided is a compound or a pharmaceutically acceptable salt thereof which is superior in an action inducing degradation of BRD4 protein and useful as a therapeutic agent for cancer. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the DESCRIPTION.
    Type: Grant
    Filed: July 20, 2023
    Date of Patent: February 6, 2024
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Kiyomi Ohba, Yasuki Niwa, Tetsuji Matsudaira, Maiko Hamada, Ryuta Yamazaki, Tatsuya Ibuki
  • SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF
    Publication number: 20230364105
    Abstract: Provided is a compound or a pharmaceutically acceptable salt thereof which is superior in an action inducing degradation of BRD4 protein and useful as a therapeutic agent for cancer. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the DESCRIPTION.
    Type: Application
    Filed: July 20, 2023
    Publication date: November 16, 2023
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Kiyomi OHBA, Yasuki NIWA, Tetsuji MATSUDAIRA, Maiko HAMADA, Ryuta YAMAZAKI, Tatsuya IBUKI
  • SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF
    Publication number: 20230146717
    Abstract: Provided is a compound or a pharmaceutically acceptable salt thereof which is superior in an action inducing degradation of BRD4 protein and useful as a therapeutic agent for cancer. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the DESCRIPTION.
    Type: Application
    Filed: February 5, 2021
    Publication date: May 11, 2023
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Kiyomi OHBA, Yasuki NIWA, Tetsuji MATSUDAIRA, Maiko HAMADA, Ryuta YAMAZAKI, Tatsuya IBUKI
  • Imide derivatives and use thereof as medicine
    Patent number: 10407408
    Abstract: Provided is a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2. The present invention relates to a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION. The compound has a selective MMP-9 production suppressive action, and is useful as a drug for the prophylaxis and/or treatment of autoimmune diseases such as rheumatoid arthritis and the like, inflammatory bowel diseases (ulcerative colitis, Crohn's disease) or osteoarthritis.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: September 10, 2019
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Seigo Ishibuchi, Kunio Saruta, Maiko Hamada, Nobuatsu Matoba, Tetsuji Matsudaira, Maki Seki, Akiko Tarao, Takashi Honjo, Shingo Ogata, Atsushi Kawata, Kenji Morokuma, Naoto Fujie, Yukio Aoyama
  • NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE
    Publication number: 20190077787
    Abstract: Provided is a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2. The present invention relates to a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION. The compound has a selective MMP-9 production suppressive action, and is useful as a drug for the prophylaxis and/or treatment of autoimmune diseases such as rheumatoid arthritis and the like, inflammatory bowel diseases (ulcerative colitis, Crohn's disease) or osteoarthritis.
    Type: Application
    Filed: July 8, 2016
    Publication date: March 14, 2019
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Seigo ISHIBUCHI, Kunio SARUTA, Maiko HAMADA, Nobuatsu MATOBA, Tetsuji MATSUDAIRA, Maki SEKI, Akiko TARAO, Takashi HONJO, Shingo OGATA, Atsushi KAWATA, Kenji MOROKUMA, Naoto FUJIE, Yukio AOYAMA
  • Oxime derivative and preparations thereof
    Patent number: 8119626
    Abstract: The problem of the present invention is to provide a useful compound as a glucokinase activating agent, which is the oxime derivative of the formula [I]: wherein Ring A is aryl or heteroaryl; Q is cycloalkyl, heterocycle, alkyl or alkenyl; Ring T is heteroaryl or heterocycle; R1 and R2 are independently hydrogen atom, halogen atom, cycloalkylsulfonyl or the like; R3 and R4 are independently hydrogen atom, hydroxy, oxo, halogen atom or the like; R5 is hydrogen atom, halogen atom, cyano, nitro, tetrazolyl or the like; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 20, 2008
    Date of Patent: February 21, 2012
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Kazutoshi Sugawara, Tetsuji Matsudaira, Hiroshi Sugama, Masao Nawano, Rikiya Ohashi
  • OXIME DERIVATIVE AND PREPARATIONS THEREOF
    Publication number: 20090291936
    Abstract: The problem of the present invention is to provide a useful compound as a glucokinase activating agent, which is the oxime derivative of the formula [I]: wherein Ring A is aryl or heteroaryl; Q is cycloalkyl, heterocycle, alkyl or alkenyl; Ring T is heteroaryl or heterocycle; R1 and R2 are independently hydrogen atom, halogen atom, cycloalkylsulfonyl or the like; R3 and R4 are independently hydrogen atom, hydroxy, oxo, halogen atom or the like; R5 is hydrogen atom, halogen atom, cyano, nitro, tetrazolyl or the like; or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 20, 2008
    Publication date: November 26, 2009
    Inventors: Kazutoshi Sugawara, Tetsuji Matsudaira, Hiroshi Sugama, Masao Nawano, Rikiya Ohashi
  • Oxime derivative and preparations thereof
    Patent number: 7514439
    Abstract: The problem of the present invention is to provide a useful compound as a glucokinase activating agent, which is the oxime derivative of the formula [I]: wherein Ring A is aryl or heteroaryl; Q is cycloalkyl, heterocycle, alkyl or alkenyl; Ring T is heteroaryl or heterocycle; R1 and R2 are independently hydrogen atom, halogen atom, cycloalkylsulfonyl or the like; R3 and R4 are independently hydrogen atom, hydroxy, oxo, halogen atom or the like; R5 is hydrogen atom, halogen atom, cyano, nitro, tetrazolyl or the like; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 10, 2006
    Date of Patent: April 7, 2009
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Kazutoshi Sugawara, Tetsuji Matsudaira, Hiroshi Sugama, Masao Nawano, Rikiya Ohashi
  • Oxime Derivative and Preparations Thereof
    Publication number: 20080132479
    Abstract: The problem of the present invention is to provide a useful compound as a glucokinase activating agent, which is the oxime derivative of the formula [I]: wherein Ring A is aryl or heteroaryl; Q is cycloalkyl, heterocycle, alkyl or alkenyl; Ring T is heteroaryl or heterocycle; R1 and R2 are independently hydrogen atom, halogen atom, cycloalkylsulfonyl or the like; R3 and R4 are independently hydrogen atom, hydroxy, oxo, halogen atom or the like; R5 is hydrogen atom, halogen atom, cyano, nitro, tetrazolyl or the like; or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 10, 2006
    Publication date: June 5, 2008
    Inventors: Kazutoshi Sugawara, Tetsuji Matsudaira, Hiroshi Sugama, Masao Nawano, Rikiya Chashi